Frederic Guerard - 15 Jun 2026 Form 4 Insider Report for LENZ Therapeutics, Inc. (LENZ)

Reporting relationship: Director
Issuer ticker: LENZ
Reported as of: 15 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2026, 20:18:01 UTC
Prior SEC filing: 26 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Daniel R. Chevallard, as Attorney-in-Fact

Key filing fact

Frederic Guerard filed Form 4 for LENZ Therapeutics, Inc. (LENZ) on 15 Jun 2026.

Key facts

This page summarizes Frederic Guerard's Form 4 filing for LENZ Therapeutics, Inc. (LENZ).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2026, 20:18.

Change

Previous filing in this sequence was filed on 26 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001825009 Primary reporting owner

Guerard Frederic

Relationship: Director
Address: C/O LENZ THERAPEUTICS, INC., 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Signature: /s/ Daniel R. Chevallard, as Attorney-in-Fact
Signature date: 15 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LENZ transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +22,100
Change %
Price: $0.000000^*
Shares after: 22,100
Date: 15 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,100
Exercise price: $6.63
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.